Abraxane News and Research

RSS
The U.S. Food and Drug Administration approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
NTU establishes new $60 million research institute in Nanomedicine

NTU establishes new $60 million research institute in Nanomedicine

NEJM publishes Celgene’s Abraxane phase III study results

NEJM publishes Celgene’s Abraxane phase III study results

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

FDA approves ABRAXANE chemotherapy drug for treatment of metastatic pancreatic cancer

FDA approves ABRAXANE chemotherapy drug for treatment of metastatic pancreatic cancer

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

Abraxane drug gets FDA approval for patients with advanced pancreatic cancer

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

Sorrento, IGDRASOL to present updates on IG-001 and IG-004 at joint meeting of CLINAM and ETPN

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

TGen receives donation from Seena Magowitz Foundation for pancreatic cancer research

TGen receives donation from Seena Magowitz Foundation for pancreatic cancer research

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

OncoMed highlights progress of anti-cancer biologics at AACR annual meeting

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

Sorrento Therapeutics, IGDRASOL to present updates on Cynviloq at Nanomedicine 2013 meeting

IGDRASOL to present updates on Cynviloq at AACR annual meeting

IGDRASOL to present updates on Cynviloq at AACR annual meeting

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic cancer

Combination of Abraxane and gemcitabine improves survival of patients with pancreatic cancer

Combination of Abraxane and gemcitabine improves survival of patients with pancreatic cancer

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

BioTrends tracks uptake of Yervoy and Zelboraf for advanced melanoma

BioTrends tracks uptake of Yervoy and Zelboraf for advanced melanoma

Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Study identifies how chemo drug combination kills pancreatic cancer cells

Study identifies how chemo drug combination kills pancreatic cancer cells